Ablative fractional laser-assisted treatments for keratinocyte carcinomas and its precursors–Clinical review and future perspectives
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Ablative fractional laser-assisted treatments for keratinocyte carcinomas and its precursors–Clinical review and future perspectives. / Erlendsson, Andrés M.; Olesen, Uffe H.; Haedersdal, Merete; Rossi, Anthony M.
I: Advanced Drug Delivery Reviews, Bind 153, 2020, s. 185-194.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Ablative fractional laser-assisted treatments for keratinocyte carcinomas and its precursors–Clinical review and future perspectives
AU - Erlendsson, Andrés M.
AU - Olesen, Uffe H.
AU - Haedersdal, Merete
AU - Rossi, Anthony M.
PY - 2020
Y1 - 2020
N2 - Keratinocyte carcinomas (KC) are the most common malignant human neoplasms. Although surgery and destructive approaches are first-line treatments, topical therapies are commonly used. Due to limited uptake of topical agents across the skin barrier, clearance rates are often sub-optimal. In pre-clinical investigations, ablative fractional laser (AFL)-assisted drug delivery has demonstrated improved uptake of topical drugs commonly used to treat KC. In 22 clinical trials, the effect of AFL-assisted treatments has been investigated for actinic keratosis (AK; n = 14), Bowen's disease (BD; n = 5), squamous cell carcinoma (n = 1), and basal cell carcinoma (n = 7). The most substantial evidence currently exists for AFL-assisted photodynamic therapy for the treatment of AK and BD. AFL improved 12-months follow-up clearance rates of photodynamic therapy from 45.0–51.0% to 78.5–84.8% for AK and from 50.0–55.3% to 87.0–87.5% for BD. AFL-assisted pharmacological therapy is a promising tool for optimizing topical treatments of KC and its precursor lesions. Future developments include AFL-assisted immune activation, changing drug administration route of systemic therapies, and utilizing drug chemo-combinations.
AB - Keratinocyte carcinomas (KC) are the most common malignant human neoplasms. Although surgery and destructive approaches are first-line treatments, topical therapies are commonly used. Due to limited uptake of topical agents across the skin barrier, clearance rates are often sub-optimal. In pre-clinical investigations, ablative fractional laser (AFL)-assisted drug delivery has demonstrated improved uptake of topical drugs commonly used to treat KC. In 22 clinical trials, the effect of AFL-assisted treatments has been investigated for actinic keratosis (AK; n = 14), Bowen's disease (BD; n = 5), squamous cell carcinoma (n = 1), and basal cell carcinoma (n = 7). The most substantial evidence currently exists for AFL-assisted photodynamic therapy for the treatment of AK and BD. AFL improved 12-months follow-up clearance rates of photodynamic therapy from 45.0–51.0% to 78.5–84.8% for AK and from 50.0–55.3% to 87.0–87.5% for BD. AFL-assisted pharmacological therapy is a promising tool for optimizing topical treatments of KC and its precursor lesions. Future developments include AFL-assisted immune activation, changing drug administration route of systemic therapies, and utilizing drug chemo-combinations.
KW - Ablative fractional laser
KW - Actinic keratoses
KW - Bowen's disease
KW - Combination therapy
KW - Immunotherapy
KW - Laser-assisted drug delivery
KW - Non-melanoma skin cancer
KW - Non-surgical treatment
KW - Photodynamic therapy
KW - Topical delivery
U2 - 10.1016/j.addr.2020.01.001
DO - 10.1016/j.addr.2020.01.001
M3 - Review
C2 - 31923431
AN - SCOPUS:85084142383
VL - 153
SP - 185
EP - 194
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
SN - 0169-409X
ER -
ID: 260197017